The research team, led by Tolulope T. Arogundade of Redeemer’s University in Nigeria together with colleagues in Nigeria and Poland, chose the fruit fly Drosophila melanogaster for a reason. The insect’s antioxidant pathways are well conserved with those of mammals, its generation time allows entire life-course experiments to be completed in weeks, and its larval crawling and feeding behaviors provide quantifiable readouts of neurological function. Crucially, the fly allows researchers to isolate the developmental period with precision: larvae were reared from their first instar through pupation and eclosion on food containing the test compounds, after which the treatment ceased entirely. Any differences seen in adulthood therefore represent latent programming effects rather than ongoing toxicity.

The toxicant in question was manganese, an element with a double identity. It is essential for life, serving as a cofactor for manganese superoxide dismutase and a suite of other enzymes, yet at elevated levels it is a recognized neurotoxicant. Human epidemiological studies have linked early-life manganese exposure, whether from contaminated drinking water or occupational settings, to cognitive deficits, motor impairments, and neuropsychiatric symptoms that often emerge insidiously years later. In the experiment, larvae were exposed to manganese chloride at two concentrations, 0.5 and 3.0 millimolar, doses selected and validated through pilot survival assays to represent a sub-clinical level and a biologically active but non-lethal level. Against this, the researchers tested quercetin, a flavonoid abundant in onions and apples, at 0.25 and 1.0 millimolar.

The behavioral results painted a nuanced picture. Larvae raised on high-dose manganese crawled dramatically shorter distances than controls, covering just 1.8 centimeters in one minute compared with 2.6 centimeters for untreated animals, a dose-dependent impairment that was statistically significant. Their feeding was also disturbed, with mouth-hook contractions running roughly fifteen percent faster than controls, a hyperactive pattern that suggests the sensory-motor circuitry governing feeding had been perturbed. Yet when those same larvae eclosed into adults and were tested five days later in the rapid iterative negative geotaxis assay, which measures climbing ability, the deficits had largely vanished. Adult climbing performance was indistinguishable from controls across all treatment groups. The molecular damage, however, told a very different story.

Biochemical assays of young adult flies revealed that the manganese-exposed animals carried a persistent oxidizing burden. Hydrogen peroxide, a central reactive oxygen species, accumulated to 3.8 nanomoles per milligram of protein in the high-dose manganese group, more than double the 1.8 nanomoles measured in controls, a difference that was highly significant. This accumulation occurred despite the fact that the activities of the classic antioxidant enzymes superoxide dismutase and catalase were largely preserved, suggesting that manganese disrupts redox balance not by crippling the enzyme defenses but by overwhelming the system at its source. The authors point to manganese’s established capacity to interfere with mitochondrial electron transport, particularly at complex II, and to drive Fenton-like chemistry that generates hydroxyl radicals from hydrogen peroxide.

The genomic consequences were the study’s most dramatic finding. Using a diphenylamine colorimetric assay to quantify the DNA fragmentation index, the researchers found that high-dose manganese pushed fragmentation to approximately 54 percent, compared with 29 percent in controls, an increase of roughly 85 percent. In other words, adult flies that had never touched manganese since emerging from their pupal cases carried genomes riddled with damage seeded during their larval feeding. The mechanism is likely multipronged: hydroxyl radicals derived from elevated hydrogen peroxide attack DNA to produce lesions such as 8-oxoguanine, and manganese ions can directly inhibit OGG1, the glycosylase enzyme that initiates repair of that very lesion, by displacing the magnesium ion in its active site. Damage production and damage repair are compromised simultaneously.

A parallel story unfolded in the realm of protein damage. Advanced glycation end-products, or AGEs, irreversible protein modifications produced when lipid peroxidation byproducts such as malondialdehyde react with amino acid residues, accumulated 57 percent above control levels in the high-dose manganese group, reaching 58 nanograms per milligram of protein versus 37 in controls. AGEs are more than passive markers of wear. When they modify components of the MRE11-RAD50-NBS1 complex, the cellular machinery that senses and initiates repair of DNA double-strand breaks, they can blunt the DNA damage response itself. The correlation between elevated DNA fragmentation and elevated glycation in the manganese-exposed flies suggests a self-amplifying cycle in which oxidative and glycative stress each feed the other, degrading both genome and proteome together.

Quercetin told the opposite tale. Flies developmentally exposed to the lower dose of the flavonoid showed enhanced catalase activity, roughly 28 percent above control levels, while maintaining basal hydrogen peroxide concentrations and showing no behavioral deficits at any stage. Their DNA fragmentation index trended downward, with the 0.25 millimolar group averaging around 14 percent, roughly half the control value, although this reduction fell just short of statistical significance. AGE levels in this group were 32 percent below controls, a significant decrease. The selective boost to catalase aligns with quercetin’s known ability to activate the Keap1-Nrf2 antioxidant signaling axis, whose fly ortholog, CncC, directly regulates catalase transcription under oxidative challenge. Notably, the higher quercetin dose failed to produce further benefits, echoing the biphasic behavior of flavonoids, which at high concentrations can undergo autoxidation and paradoxically generate reactive species.

Why did the manganese-exposed adults climb normally while their larval selves had crawled poorly, and while their molecules told a story of damage? The authors propose several non-exclusive explanations. Compensatory mechanisms such as autophagy-mediated clearance of damaged proteins and synaptic homeostatic plasticity may buffer locomotor circuits against moderate developmental insults, preserving function even as molecular wear accumulates beneath the surface. Alternatively, the five-day post-eclosion assessment may simply capture a pre-symptomatic stage, with late-onset motor decline emerging in older flies as accumulated DNA damage crosses a functional threshold. This latter possibility carries obvious translational weight, given that human manganese-associated neurological deficits also tend to manifest years after the initial exposure window. The researchers suggest that monitoring biomarkers such as plasma AGEs and urinary 8-oxodG in children from manganese-endemic regions could enable early risk stratification before symptoms appear.

The study has honest limits. Quercetin was never given concurrently with manganese, so the experiment speaks to independent programming effects rather than direct rescue, and the authors explicitly call a co-treatment trial the priority next step. Sex-specific vulnerabilities were not assessed, the adult endpoint was a single time point, and mechanistic pathways were inferred rather than genetically validated. Still, the central message lands with force: hydrogen peroxide levels and DNA fragmentation indices emerge as sensitive biomarkers of latent developmental toxicant injury, and low-dose dietary antioxidants appear capable of priming antioxidant defenses during critical windows without harm. In a world where manganese exposure affects communities near industrial sites and contaminated water supplies worldwide, the idea that a common dietary flavonoid might tip the developmental balance toward resilience, rather than vulnerability, is a proposition worth serious investigation in mammalian models.

Subject of Research: Developmental programming of adult oxidative stress, DNA damage and behaviour by manganese or quercetin in Drosophila melanogaster

Article Title: Developmental exposure to manganese or quercetin differentially programs adult oxidative stress, DNA fragmentation and behaviour in Drosophila

Article References: Arogundade, T. T., Olatomide, O. D., Adeleye, D. A., Ikegulu, P. S., Akinfaye, M. O., Arogundade, O. A., Omotoso, D. R., & Gbadamosi, I. (2026). Developmental exposure to manganese or quercetin differentially programs adult oxidative stress, DNA fragmentation and behaviour in Drosophila. Discover Toxicology, 3(1), Article 9. https://doi.org/10.1007/s44339-026-00054-0

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00054-0

Keywords: manganese, quercetin, Drosophila, oxidative stress, DNA fragmentation, developmental programming, neurotoxicology, advanced glycation end-products, hydrogen peroxide, catalase, Nrf2 signaling, flavonoids

LRRK2, short for leucine-rich repeat kinase 2, functions as a scaffold and enzyme that integrates signals through GTPase, kinase, and protein-interaction domains distributed across its roughly 2,800 amino acids. Pathogenic mutations concentrated in the ROC-COR-kinase superfamily domain increase kinase output, and this excess activity drives a characteristic cellular phenotype: exaggerated phosphorylation of the Rab family of small GTPases, which act as master regulators of intracellular vesicle trafficking. When Rab proteins are over-phosphorylated, the endolysosomal system, the cellular machinery responsible for sorting membranes, digesting debris, and recycling receptors, becomes sluggish and disorganized. In neurons, whose elaborate axons and synapses depend heavily on vesicle logistics, the consequences include autophagic dysfunction, impaired clearance of damaged mitochondria, accumulation of alpha-synuclein aggregates, and ultimately compromised cell survival.

Fatty acid nitroalkenes, including well-studied congeners such as nitro-oleic acid and nitro-linoleic acid, arise endogenously when nitric oxide and nitrite-derived species react with unsaturated lipids during oxidative and inflammatory processes. Far from being inert byproducts, these molecules act as signaling mediators that undergo reversible covalent addition to nucleophilic residues on target proteins, a mechanism biologists describe as electrophilic reaction with subsequent reversible Michael addition. Because the modifications are reversible, nitroalkenes can transiently modulate the activity of numerous proteins involved in inflammatory, stress-response, and metabolic pathways rather than irreversibly damaging them. This property has fueled interest in the compounds as pharmacological agents, and synthetic variants have been developed that resist metabolic degradation while retaining the reversible covalent chemistry that underlies their biological effects.

Previous work had established that nitro-fatty acids activate the Nrf2 transcriptional program, the cell’s principal antioxidant defense, and blunt inflammatory signaling through effects on pathways such as NF-kappaB. The new findings extend this repertoire into kinase-directed neuroprotection. In cellular models engineered to express hyperactive LRRK2, treatment with fatty acid nitroalkenes reduced LRRK2 kinase activity toward its Rab substrates, reversing the over-phosphorylation signature that defines pathological states. The magnitude of inhibition brought aberrant Rab signaling back toward baseline levels, suggesting that the compounds act on the disease-relevant mechanism rather than merely masking downstream symptoms.

The mechanistic picture that emerges is one in which nitroalkenes engage the kinase domain or associated regulatory regions of LRRK2 through their characteristic electrophilic chemistry, dampening enzymatic output. Because reversible covalent modification can influence protein conformation and interactions, the compounds plausibly stabilize LRRK2 in a less active configuration or interfere with the autophosphorylation events that sustain activity. Critically, the inhibition did not require the gross catalytic blockade associated with some ATP-competitive LRRK2 inhibitors, molecules that have progressed to clinical trials but raised safety concerns after producing changes in lung tissue in animal studies, including structures resembling surfactant accumulation. A lipid-derived modulator with partial or pathway-selective inhibition could therefore sidestep some of the on-target toxicities that have complicated the kinase-inhibitor approach.

Neuroprotection in the disease models followed the correction of kinase signaling. Dopamine-relevant neuronal populations that normally succumb under conditions of LRRK2 hyperactivation survived at higher rates when nitroalkenes were present. The protective effect tracked with restoration of vesicle-trafficking markers and improvement in lysosomal function, consistent with the hypothesis that rescuing the endolysosomal axis is what spares the cells. The findings also align with epidemiological and genetic observations: LRRK2 variants that increase kinase activity raise Parkinson’s risk, while variants that dampen activity are protective, and carriers of hyperactive alleles show Parkinson-like pathology even without clinical disease, including enlarged lysosomes in peripheral immune cells and vesicular abnormalities in urinary cells. If hyperactive LRRK2 acts as a chronic accelerant of degeneration, interventions that normalize its activity early in the disease process could alter trajectory in ways that symptomatic dopamine replacement cannot.

The intersection with inflammation adds a second layer of plausibility. Microglia, the resident immune cells of the brain, depend on lysosomal function to clear protein aggregates and cellular debris, and LRRK2 hyperactivity in these cells has been linked to exaggerated inflammatory output and impaired phagocytosis. Nitroalkenes, with their established capacity to resolve inflammatory signaling through Nrf2 activation and inhibition of pro-inflammatory transcription factors, simultaneously address the stress-response deficit that leaves aging neurons vulnerable and the neuroinflammatory amplification loop that spreads damage through neural circuits. A single molecule class acting on both a primary genetic risk mechanism and the secondary inflammatory cascade is an unusual and attractive pharmacological profile.

Considerable distance nonetheless remains between cellular and animal models and therapies for patients. Nitro-fatty acids have previously entered early-phase human testing for metabolic and inflammatory indications, which provides a foundation of tolerability data, but achieving and sustaining adequate concentrations in the brain demands proof of blood-brain barrier penetration and pharmacokinetics suited to chronic use. Dosing, the durability of kinase normalization, and possible interactions with the lipid milieu of aging brains all require careful study. Questions also persist about which patient populations stand to benefit most; LRRK2 mutation carriers are obvious candidates, but the reported presence of elevated LRRK2 activity in idiopathic disease hints at a much broader treatment population, one that biomarkers for Rab phosphorylation, detectable in blood and urine, could help define in future trials.

Even with those caveats, the study reframes a familiar molecule class as a precision instrument against a dominant genetic driver of Parkinson’s disease. It joins a widening effort to move beyond dopamine restoration toward mechanism-targeted intervention, in which lipid electrophiles, kinase modulators, and lysosome-restoring agents are evaluated by their ability to correct measurable molecular faults. For the millions living with or at risk of Parkinson’s, the prospect that a compound derived from ordinary dietary fatty acids could quiet the kinase storm implicated in their disease represents the kind of unexpected convergence, of redox biology, lipid chemistry, and neurogenetics, that periodically reshapes therapeutic development. Follow-up work will determine whether the neuroprotection observed in models translates into slowed progression in humans, but the demonstration that fatty acid nitroalkenes can disarm LRRK2 hyperactivation gives the field a new and chemically distinctive tool with which to pursue that goal.

Subject of Research: Fatty acid nitroalkene inhibition of LRRK2 kinase hyperactivation as a neuroprotective strategy in Parkinson's disease models.

Article Title: Fatty acid nitroalkene inhibition of LRRK2 hyperactivation and induction of neuroprotection in a model of Parkinson’s disease

Article References: Fazzari, M., Sekandari, A., Stoddard, M., Odoux, C., Ekhator, E. S., Sanders, I., Castro, S., Sukoff Rizzo, S. J., Schopfer, F. J., Greenamyre, T., Freeman, B. A., & Di Maio, R. (2026). Fatty acid nitroalkene inhibition of LRRK2 hyperactivation and induction of neuroprotection in a model of Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01551-0

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01551-0

Keywords: Parkinson's disease, LRRK2, fatty acid nitroalkenes, kinase inhibition, neuroprotection, Rab phosphorylation, endolysosomal function, neurodegeneration, nitro-fatty acids, alpha-synuclein, Nrf2 signaling, dopamine neurons